INT'L GROUP(000411)

Search documents
英特集团2025年一季度业绩下滑,需关注现金流与债务状况
Zheng Quan Zhi Xing· 2025-04-28 23:05
Performance Overview - The company reported a decline in performance for Q1 2025, with total revenue of 8.437 billion yuan, a year-on-year decrease of 1.87% [1] - The net profit attributable to shareholders was 101 million yuan, down 5.7% year-on-year, while the net profit excluding non-recurring items was 98.678 million yuan, a decrease of 4.54% [1] Profitability Analysis - The company's gross margin stood at 6.0%, a decrease of 6.35 percentage points year-on-year, and the net profit margin was 1.41%, down 5.55 percentage points [2] Expense Control - Total operating expenses (selling, administrative, and financial expenses) amounted to 301 million yuan, with an expense-to-revenue ratio of 3.57%, which is a year-on-year reduction of 12.12% [3] Asset and Cash Flow Situation - The company's cash and cash equivalents were 1.114 billion yuan, a decline of 29.75% compared to 1.586 billion yuan in the same period last year [4] - Operating cash flow per share was -5.11 yuan, a decrease of 39.28% year-on-year, indicating significant challenges in cash flow management [4] Accounts Receivable and Debt Situation - As of the end of the reporting period, accounts receivable amounted to 8.402 billion yuan, an increase of 5.44% year-on-year, with interest-bearing debt at 4.294 billion yuan, down 2.95% [5] - The ratio of accounts receivable to profit was as high as 1598.78%, necessitating close monitoring of collection [5] Business Model and Capital Return - Over its 29 years since listing, the company has raised a total of 2.272 billion yuan and distributed dividends totaling 332 million yuan, resulting in a dividend-to-financing ratio of 0.15 [6] - The company's performance heavily relies on equity financing and marketing efforts, raising questions about the sustainability of this business model [6] Summary - Overall, the company's performance in Q1 2025 was unsatisfactory, particularly in terms of profitability, cash flow management, and accounts receivable, which pose significant risks [7]
英特集团(000411) - 2025 Q1 - 季度财报
2025-04-27 07:35
Revenue and Profitability - Revenue for Q1 2025 was CNY 8,436,943,741.35, a decrease of 1.87% compared to CNY 8,597,940,087.94 in the same period last year[5] - Net profit attributable to shareholders was CNY 100,801,310.48, down 5.70% from CNY 106,894,805.02 year-over-year[5] - Basic earnings per share decreased by 6.10% to CNY 0.1941 from CNY 0.2067 in the previous year[5] - Total operating revenue for the current period was ¥8,436,943,741.35, a decrease of 1.87% from ¥8,597,940,087.94 in the previous period[18] - Net profit for the current period was ¥119,122,931.68, down 7.06% from ¥128,524,787.80 in the previous period[18] - Basic earnings per share decreased to CNY 0.1941 from CNY 0.2067, indicating a decline in profitability on a per-share basis[19] - Diluted earnings per share also fell to CNY 0.1854 from CNY 0.1974, further highlighting the decrease in earnings[19] Assets and Liabilities - Total assets increased by 11.67% to CNY 16,340,244,312.38 from CNY 14,632,477,002.42 at the end of the previous year[5] - Current liabilities rose significantly to ¥10,318,108,652.14 from ¥8,739,555,232.39, an increase of 18.06%[16] - The company's total assets increased to ¥16,340,244,312.38 from ¥14,632,477,002.42, representing a growth of 11.66%[16] - The total equity attributable to the parent company increased to ¥4,739,552,708.65 from ¥4,637,220,801.37, a rise of 2.20%[16] Cash Flow - Cash flow from operating activities showed a negative net amount of CNY -2,664,749,856.70, worsening from CNY -1,914,183,258.10 in the previous year[5] - The net cash flow from operating activities decreased significantly to -2,664,749,856.70, primarily due to a reduction in cash received from sales and an increase in cash paid for purchases and services[10] - The cash and cash equivalents decreased by 3,282.40% to -424,517,843.97, primarily due to reduced net cash flow from operating activities[10] - The total cash and cash equivalents at the end of the period were CNY 850,578,247.41, down from CNY 1,349,592,698.39 in the previous period[21] - The net increase in cash and cash equivalents was CNY -424,517,843.97, contrasting with a net increase of CNY 13,339,537.64 in the previous period, indicating cash flow challenges[21] Investments and Expenditures - Research and development expenses rose significantly by 126.10% to CNY 4,552,638.58, primarily due to increased investment in the cold chain logistics project[9] - Cash outflow for the acquisition of fixed assets and other long-term assets rose by 77.37% to 32,937,456.96, attributed to increased investments in renovation projects[10] - The company invested CNY 32,937,456.96 in fixed assets, intangible assets, and other long-term assets, a substantial increase from CNY 18,569,626.50 in the previous period[21] Financing Activities - Short-term borrowings surged by 106.02% to CNY 3,651,826,139.26, mainly due to increased bank loans[9] - The company received cash of 153,000,000.00 related to financing activities, primarily from commercial acceptance bill discounts[10] - Cash inflow from financing activities increased to CNY 3,760,132,308.44, up from CNY 3,202,490,084.20 in the previous period, reflecting a stronger financing position[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,329[12] - Zhejiang International Trade Group Co., Ltd. held 28.90% of shares, making it the largest shareholder with 150,846,487 shares[12] - Zhejiang Pharmaceutical Health Industry Group Co., Ltd. owned 23.43% of shares, totaling 122,277,151 shares[12] Tax and Subsidies - The company received government subsidies amounting to CNY 5,156,166.48, contributing positively to the financial results[6] - The net cash received from tax refunds increased significantly by 1,112.86% to CNY 346,148.04 compared to CNY 28,539.75 in the previous year[9] - The company received CNY 346,148.04 in tax refunds, significantly higher than CNY 28,539.75 in the previous period, indicating improved tax recovery[20]
英特集团2024年度拟派2亿元红包
Zheng Quan Shi Bao Wang· 2025-04-24 14:18
公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计(亿元) | 股息率(%) | | --- | --- | --- | --- | | 2024.12.31 | 10派3.83元(含税) | 2.00 | 3.63 | | 2023.12.31 | 10派3.045元(含税) | 1.59 | 2.42 | | 2022.12.31 | 10派1.260239元(含税) | 0.64 | 0.98 | | 2021.12.31 | 10转增2派1.999562元(含税) | 0.51 | 1.41 | | 2020.12.31 | 10派0.65元(含税) | 0.16 | 0.33 | | 2019.12.31 | 10派0.61元(含税) | 0.15 | 0.46 | | 2018.12.31 | 10派1.3元(含税) | 0.27 | 0.84 | | 2007.12.31 | 10转增8股 | 0.00 | 0.00 | 证券时报·数据宝统计显示,公司今日公布了2024年报,共实现营业收入333.52亿元,同比增长4.05%, 实现净利润5.26亿元,同比增长7.53%,基本 ...
英特集团(000411) - 关于英特药业为英特集团合并范围内的子公司融资提供担保的公告
2025-04-24 09:17
| 证券代码:000411 | 证券简称:英特集团 | 公告编号:2025-019 | | --- | --- | --- | | 债券代码:127028 | 债券简称:英特转债 | | 浙江英特集团股份有限公司 关于英特药业为英特集团合并范围内的子公司融资提供担 保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或 重大遗漏。 2025 年4 月23 日,浙江英特集团股份有限公司(以下简称"英特集团"或"公司")十届十次 董事会议以"10 票同意、0 票反对、0 票弃权"审议通过了《关于英特药业为英特集团合并范围内的 子公司融资提供担保的议案》,现将具体情况公告如下: 一、担保情况概述 公司全资子公司浙江英特药业有限责任公司(以下简称"英特药业")为支持英特集团 合并报表范围内子公司的项目建设和业务发展,拟在 2025-2026 年提供融资担保,担保总额 为 117,000 万元,具体情况如下: (1)拟为英特集团全资子公司提供担保的情况: 单位:万元 | 被担保方 | 2024 年末 | 截至 2025 | | 本次担 | 担保额度占上市 | 是否 | | --- ...
英特集团(000411) - 内部控制自我评价报告
2025-04-24 09:17
浙江英特集团股份有限公司 2024 年度内部控制评价报告 浙江英特集团股份有限公司全体股东: 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求(以下简 称"企业内部控制规范体系"),结合公司内部控制制度和评价办法,在内部控制日常监督 和专项监督的基础上,我们对公司 2024 年 12 月 31 日(内部控制评价报告基准日)的内部 控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定,建立健全和有效实施内部控制,评价其有效性,并 如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行 监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏,并对报告内容 的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真 实完整,提高经营效率和效果,促进实现发展战略。由于内部控制存在的固有局限性,故仅 能为实现上述目标提供合理保证。此外,由于情况的变化可能导致内部控制变得不恰当,或 对控制政策和程序遵 ...
英特集团(000411) - 关于重大资产重组2024年度业绩承诺实现情况说明的公告
2025-04-24 09:17
| 证券代码:000411 | 证券简称:英特集团 | 公告编号:2025-017 | | --- | --- | --- | | 债券代码:127028 | 债券简称:英特转债 | | 浙江英特集团股份有限公司 关于重大资产重组 2024 年度业绩承诺实现情况说明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导 性陈述或重大遗漏。 浙江英特集团股份有限公司(以下简称"公司")于2025年4月23日召开公司十届十次董事 会议,以"10票同意,0票反对,0票弃权"审议通过了《关于重大资产重组2024年度业绩承 诺实现情况说明的议案》。公司于2023年向交易对方浙江省国际贸易集团有限公司(以下简 称"国贸集团")、浙江华辰投资发展有限公司(以下简称"华辰投资")以发行股份及支 付现金的方式,购买国贸集团和华辰投资合计持有的浙江英特药业有限责任公司(以下简称 "英特药业""标的公司")50%股权。根据深圳证券交易所相关规定,现将英特药业2024 年度业绩承诺完成情况说明如下: 一、本次交易的基本情况 公司于2022年5月25日召开九届十五次董事会议和九届十一次监事会议,2022年 ...
英特集团(000411) - 2024年度年审会计师履职情况评估报告
2025-04-24 09:17
浙江英特集团股份有限公司 2024 年度年审会计师履职情况评估报告 浙江英特集团股份有限公司(以下简称"公司")聘请天健会计师事务所(特殊普通合伙) (以下简称"天健")作为公司 2024 年度年报审计机构。根据财政部、国资委及证监会颁布的 《国有企业、上市公司选聘会计师事务所管理办法》,公司对天健 2024 年审计过程中的履 职情况进行评估。经评估,公司认为天健资质等方面合规有效,履职保持独立性,勤勉尽责, 公允表达意见,具体情况如下: 一、资质条件 1、基本信息 | 事务所名称 | 天健会计师事务所(特殊普通合伙) | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 年 月 组织形式 2011 18 | 7 | 日 | | | 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 128 号 | | | | | | | 首席合伙人 | 钟建国 上年末合伙人数量 | | | | 241 | 人 | | 上年末执业人员数量 | 注册会计师 | | | | 2,356 | 人 | | | 签署过证券服务业务审计报告的注 ...
英特集团(000411) - 2024年度监事会报告
2025-04-24 09:17
浙江英特集团股份有限公司 2024 年度监事会报告 2024 年,浙江英特集团股份有限公司(以下简称"公司")监事会完成了换届选举工作, 新一届监事会严格遵循《公司法》《证券法》等法律法规,以及《公司章程》和《监事会议 事规则》等相关制度的规定,本着对公司、对全体股东负责的精神,认真履行监事会职责, 积极开展相关工作,列席或出席公司召开的董事会、股东会,对会议的召开程序、公司经营 活动、财务状况、重大决策及董事、高级管理人员履行职责情况进行了有效监督,促进公司 持续、健康、稳定的发展。现将公司监事会 2024 年的工作情况汇报如下: 一、2024 年度监事会工作情况 (一)依法运作情况 各位监事除认真参加公司监事会会议以外,积极列席并出席公司的历次董事会和股东大 会会议,结合自身专业,针对会议议案认真质询、建言献策,切实履行监事的职责,充分发 挥监督作用。监事会认为公司拥有完善的内部控制制度,能够合规高效地开展各项经营活动, 公司股东大会、董事会、监事会的召集、召开、表决、决议程序合法有效,董事会认真执行 股东大会的各项决议,忠实履行职责。 (二)财务管理情况 监事会对公司定期报告、财务报表以及财务状况进行了 ...
英特集团(000411) - 2024年度财务决算报告
2025-04-24 09:17
浙江英特集团股份有限公司 单位:元 | | 年 2024 | 年 2023 | 本年比上年 增减 | | --- | --- | --- | --- | | 营业收入(元) | 33,351,653,828.95 | 32,052,121,586.44 | 4.05% | | 归属于上市公司股东的净利润(元) | 525,522,107.14 | 488,732,096.82 | 7.53% | | 归属于上市公司股东的扣除非经常性 损益的净利润(元) | 509,880,346.81 | 405,498,097.75 | 25.74% | | 经营活动产生的现金流量净额(元) | 410,324,781.82 | 425,313,727.37 | -3.52% | | 基本每股收益(元/股) | 1.02 | 1.09 | -6.42% | | 稀释每股收益(元/股) | 0.96 | 1.03 | -6.80% | | 加权平均净资产收益率 | 11.87% | 14.02% | -2.15% | | | 2024 年末 | 2023 年末 | 本年末比上 年末增减 | | 总资产(元) | 14,632 ...
英特集团(000411) - 董事会审计委员会对 2024年度年审会计师履行监督职责情况报告
2025-04-24 09:17
一、2024 年年审会计师事务所基本情况 (一)会计师事务所基本情况 截至 2024 年 12 月 31 日,天健会计师事务所(特殊普通合伙)(以下简称"天健")基本 情况如下: | 事务所名称 | 天健会计师事务所(特殊普通合伙) | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 年 月 18 组织形式 | 7 | 日 | | | | 特殊普通合伙 | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 128 号 | | | | | | | | | 首席合伙人 | 钟建国 | | | | 上年末合伙人数量 | 241 | 人 | | | 上年末执业人员数量 | 注册会计师 | | | | | | 2,356 | 人 | | | 签署过证券服务业务审计报告的注册会计师 | | | | | 904 | 人 | | | 2023 | 业务收入总额 | | | 34.83 | 亿元 | | | | | 年(经审计)业 务收入 | 审计业务收入 | | | 30.99 | 亿元 | | | ...